According to ASCO, the outlook for individuals with cancer is starkly different than 50 years ago. Today, people with some of the most common cancers routinely live for years after being diagnosed, and some cancers previously considered untreatable are responding to recent advances in precision medicine and immunotherapy. Next-generation treatments are also making their way through clinical trials and they may offer new hope to millions of patients.
AdisInsight is helping researchers in academia, biotech, and pharma keep pace with the rapid development in oncology. AdisInsight (adisinsight.springer.com) is an integrated database of profiles authored by Springer Nature editors sourced from publicly available information from journals, conferences, trial registries, media releases, company websites, and government filings about pharmaceutical development programs, clinical trial studies, and published individual case safety reports. Information in AdisInsight is updated daily to keep you informed of the latest information impacting your research.